Gilead Sciences Files 8-K on Financials
Ticker: GILD · Form: 8-K · Filed: Oct 30, 2025 · CIK: 882095
| Field | Detail |
|---|---|
| Company | Gilead Sciences, INC. (GILD) |
| Form Type | 8-K |
| Filed Date | Oct 30, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: GILD
TL;DR
Gilead dropped an 8-K today, check the financials.
AI Summary
Gilead Sciences, Inc. filed an 8-K on October 30, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with no specific financial figures or operational details provided in this summary.
Why It Matters
This filing indicates Gilead Sciences is providing an update on its financial performance and condition to the SEC, which is important for investors to monitor the company's health.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not contain any immediate news that would suggest a change in risk.
Key Players & Entities
- GILEAD SCIENCES, INC. (company) — Registrant
- October 30, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 333 Lakeside Drive, Foster City, California 94404 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Gilead Sciences, Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
On what date was this 8-K filing reported?
This 8-K filing was reported on October 30, 2025.
What is the principal executive office address for Gilead Sciences, Inc.?
The principal executive office address for Gilead Sciences, Inc. is 333 Lakeside Drive, Foster City, California 94404.
In which state was Gilead Sciences, Inc. incorporated?
Gilead Sciences, Inc. was incorporated in Delaware.
What is the IRS Employer Identification Number for Gilead Sciences, Inc.?
The IRS Employer Identification Number for Gilead Sciences, Inc. is 94-3047598.
Filing Stats: 678 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2025-10-30 16:04:07
Key Financial Figures
- $0.001 — ch registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select
Filing Documents
- gild-20251030.htm (8-K) — 31KB
- exhibit991earningspressrel.htm (EX-99.1) — 690KB
- gilead_transparentxlogoxst.jpg (GRAPHIC) — 36KB
- 0000882095-25-000044.txt ( ) — 923KB
- gild-20251030.xsd (EX-101.SCH) — 2KB
- gild-20251030_lab.xml (EX-101.LAB) — 21KB
- gild-20251030_pre.xml (EX-101.PRE) — 12KB
- gild-20251030_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On October 30, 2025 , Gilead Sciences, Inc., a Delaware corporation ("Gilead"), announced its financial results for the quarter ended September 30, 2025. A copy of the press release is filed as Exhibit 99.1 to this report. Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles ("GAAP") and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under GAAP. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 9, 10 and 11 of the press release filed as Exhibit 99.1 to this report. The information in Item 2.02 and Item 9.01 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing. Section 9 - FINANCIAL STATEMENTS AND EXHIBITS
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, issued by Gilead Sciences, Inc. on October 30, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GILEAD SCIENCES, INC. (Registrant) /s/ ANDREW D. DICKINSON Andrew D. Dickinson Chief Financial Officer Date: October 30, 2025 Exhibit Index Exhibit Number Description 99.1 Press Release, issued by Gilead Sciences, Inc. on October 30, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)